Please login to the form below

Not currently logged in
Email:
Password:

Government's surplus vaccine deal with GSK

The UK's Department of Health has announced it has reached a deal with GlaxoSmithKline regarding outstanding orders of the swine flu vaccine

The UK's Department of Health (DH) has announced it has reached a deal with GlaxoSmithKline (GSK) regarding outstanding orders of the swine flu vaccine.

The deal will see the government's order for GSK's Pandemrix vaccine capped at 34.8 million doses, including those already received.

With this cap, the government will save around one third of the original value of total orders from GSK, with previous measures from the government seeing enough vaccine ordered to protect the entire population, if needed.

In light of developments concerning swine flu however, experts have advised that such a precaution is no longer necessary. The total figure of doses now represents the stock that GSK had produced for the UK and could not reasonably retract.

Although details of the agreement are commercially confidential, the DH did say there would be no cancellation fee.

Health Secretary, Andy Burnham, said: "I am pleased we have reached an agreement that is good value for the taxpayer and means that the Department has retained a strategic stockpile to protect the UK population without incurring a cancellation fee. This both protects the public purse and ensures the UK remains at the forefront of pandemic preparedness worldwide."

Unused vaccines will be kept in reserve in case the virus causes another wave of illness. Immunisation will also remain for patients in priority groups, such as pregnant women.

The government also intends to donate 3.8 million doses of the vaccine to the World Health Organisation (WHO) to use in Africa prior to the rainy season.

Despite the news, the DH urged that "it is essential to remain vigilant and prepared in case it [swine flu] re-emerges in the UK."

The DH also sought to remind the population of the risk of a 'bird flu', or H5N1 virus, pandemic, saying the risk "remains just as likely as before the current pandemic and it is prudent that the UK maintains a stockpile of vaccine that is licensed and ready to use."

Part of the deal with GSK will see the DH receive H5N1 virus vaccines and courses of the antiviral Relenza to replace the amount used during the swine flu outbreak.

The WHO has retained a pandemic alert phase III for the H5N1 virus, with the cumulative number of confirmed human cases of 'bird flu' reported to WHO standing at 489 as of March 10, 2010, with 289 deaths.

"The probability of a 'bird flu' pandemic, which is likely to be more severe than swine flu, has not diminished," said Burnham.

"This agreement means we are ready if a 'bird flu' pandemic occurred, and allows us to maintain our status as one of the most prepared countries in the world."

6th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....